EVALUATION OF SAFETY AND EFFICACY OF DAPAGLIFLOZIN AS FIRST LINE MONOTHERAPY WITH METFORMIN IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS - A RANDOMIZED OPEN LABEL STUDY
Main Article Content
Keywords
Type 2 Diabetes, Dapagliflozin, Metformin, Monotherapy, Blood Glucose
Abstract
Dapagliflozin, an SGLT2 inhibitor, is compared to Metformin monotherapy in patients with newly diagnosed type II diabetes. Patients newly diagnosed with Type II Diabetes Mellitus were included in the study. It was conducted at the Non-Communicable Disease (NCD) Clinic, under the General Medicine Department at Sri Lalithambigai Medical College and Hospital from February 2023 to February 2024. The study recruited 100 patients, 50 in each arm. As a result of dapagliflozin treatment, patients with metabolic syndrome improved all aspects of the condition. Participants receiving Dapagliflozin experienced greater decreases in body weight, body mass index, waist circumference, fasting blood glucose, and postprandial blood glucose compared to those receiving Metformin. In terms of HbA1c, HDL cholesterol, LDL cholesterol, and triglyceride levels, there were no significant differences. The Dapagliflozin group experienced a higher incidence of UTIs which can be prevented by increased intake of water when compared with the Metformin group. However, there were no serious side effects, or deaths which suggested that although Dapagliflozin increased the risk of urinary tract infections, overall safety profiles of both drugs were good. These findings suggest that Dapagliflozin may offer superior metabolic benefits compared to Metformin for Type II Diabetes Mellitus.
References
2. Gu, D. et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365(9468), 1398–1405 (2005)
3. Usman M, Siddiqi T, Memon M, Khan M, Rawasia W, Talha Ayub M et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology. 2018; 25(5):495-502.
4. Bonora B, Avogaro A, Fadini G. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020; Volume 13:161-174.
5. Scheen A. Pharmacodynamics, Efficacy and Safety of Sodium– Glucose Co-Transporter Type2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs. 2014; 75(1):33-59.
6. Haas B, Eckstein N, Pfeifer V, Mayer P, Hass M. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition & Diabetes. 2014; 4(11): e143-e143.
7. García-Ropero Á, Santos-Gallego C, Badimon J. The anti- inflammatory effects of SGLT inhibitors. Aging. 2019; 11(16):5866-5867.
8. Ashrafi Jigheh Z, Ghorbani Haghjo A, Argani H, Roshangar L, Rashtchizadeh N, Sanajou D et al. Empagliflozin Attenuates Renal and Urinary Markers of Tubular Epithelial Cell Injury in Streptozotocin-induced Diabetic Rats. Indian Journal of Clinical Biochemistry. 2018; 35(1):109-114.
9. Schweizer, A., Dejager, S. and Bosi, E. (2009), Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes, Obesity and Metabolism, 11: 804-81
10. Davies, M. J., Merton, K. W., Vijapurkar, U., Balis, D. A. & Desai, M. Canaglifozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Metab. Syndr. Obes. 10, 47–55 (2017).
11. Fuchigami, A. et al. Efcacy of dapaglifozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: A prospective, randomized study (DIVERSITY-CVR). Cardiovasc. Diabetol. 19(1), 1 (2020).
12. González-Ortiz, M., Méndez-Del Villar, M., Martínez-Abundis, E. & Ramírez-Rodríguez, A. M. Efect of dapaglifozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Minerva Endocrinol. 43(3), 229–235 (2018).
13. Henry, R. R. et al. Dapaglifozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 66(5), 446–456 (2012).
14. Jiang, J., Lin, L. & Chen, P. Comparison of dapaglifozin and liraglutide in patients with poorly controlled type 2 diabetes mellitus: A 24-week, open, double-centered, head to head trial. Endocr. Metab. Immune Disord. Drug Targets 21, 1366 (2021).
15. Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010). Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care, 33(10), 2217–2224.
16. List, J. F.,Woo, V., Morales, E., Tang,W., & Fiedorek, F. T. (2009). Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care, 32(4), 650–657.
17. Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009). Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology and Therapeutics, 85(5), 513–519.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Banupriya B
Assistant Professor, Department of Pharmacology, Faculty of Medicine, Sri Lalithambigai Medical College and Hospital, Dr. MGR Educational and Research Institute, Chennai, Tamilnadu, India.
Dr. Nandhidha R
Assistant Professor, Department of Pharmacology, Faculty of Medicine, Sri Lalithambigai Medical College and Hospital, Dr. MGR Educational and Research Institute, Chennai, Tamilnadu, India.